Early and severe keratoconus treatment options

Article

Aylin Kilic Ertan explores which keratoconus patients are most suitable for treatment with Intacs intracorneal rings.

Key Points

Options for early KC treatment

Another option for early treatment is penetrating keratoplasty, which has been associated with only limited success in younger patients. This limited success can be attributed principally to pre-, intra- and postoperative problems, because low scleral rigidity, increased intraoperative fibrin formation, and positive vitreous pressure complicate the surgical procedure.

Although some studies report Intacs improves visual acuity as well as refractive and topographical findings in keratoconic patients, the effectiveness and safety of the implant in different age groups remain unknown. To investigate further, I conducted a study comparing the response to Intacs treatment in KC patients of different ages, assessing whether an age-related increase in corneal "stiffness" could impact the outcome of Intacs treatment. At the one year follow-up point, the study did not find any statistically significant differences between young, middle and older age groups in visual acuity, manifest sphere, cylinder, mean refractive spherical equivalent (MRSE) or mean-K readings (Figure 2, Tables 1 and 2) (ANOVA, p > 0.05).5 We therefore concluded that Intacs is as safe and effective in adolescent KC patients as in other age groups.
















Intacs outcomes in severe keratoconus

Postoperatively, the stage IV group demonstrated less change in uncorrected visual acuity and more improvement in mean K values (p < 0.05, ANOVA). Six months after implantation, segment extrusions occurred in three eyes in the stage IV group: the patients were 18, 20 and 23 years old.

Improvements in visual acuity and astigmatism after implantation, in corneas with and without scarring due to keratoconic hydrops, have previously been reported.7 In that study, the BCVA improved to a greater degree in the scarring group than in the no-scarring group, and at the final follow-up visit (12 months postoperatively) Intacs had prevented the need for corneal transplantation. To our knowledge, this is the only study that suggests that patients with paracentral scarring or with corneas steeper than 57.0 D would benefit from Intacs. As our study found that Intacs implantation was effective in eyes with severe KC, however, our results support these earlier findings.

The first clinical results of the use of the femtosecond laser (which has demonstrated potential for high-precision micro machining and other applications) in Intacs treatment were reported in 2003.8 There were no intraoperative complications with the femtosecond laser in our study, and although segment extrusions occurred in three eyes during follow-up, this is less than the complication rate reported by Kanellopoulos,9 which was as high as 35%. Complications in that study included segment movement, exposure and corneal melting with mechanical tunnel dissection. The difference in complication rates may be attributed to use of the femtosecond laser method for channel creation and wide channel parameters.

Intacs recommended in all ages and stages

In both studies I conducted, in early and severe KC eyes, Intacs was a safe and effective treatment option. The efficacy of the implant was not compromised by implantation in young eyes, and although segment extrusions occurred in three stage IV eyes, the rate of complications remained low. Overall, I would recommend Intacs as a treatment whatever the age of the patient and whatever the stage of the disease. Although early treatment is recommended, Intacs implants remain effective even in eyes with severe KC.

References

1. K. Zadnik, et al. Invest. Ophthalmol. Vis. Sci. 1998 Dec;39(13):2537–2546.

2. C. Kirwan, et al. Am. J. Ophthalmol. 2006;142:990–992.

3. A. Ertan & O. Muftuoglu. Cornea 2008:27(10):1109–1113.

4. C.A. McCarty. Clin. Exp. Optom. 2002;85:91–96.

5. A. Ertan & E. Ozkilic. J. Refract. Surg. 2008;24:690–695.

6. A. Ertan & G. Kamburoglu. J. Cataract Refract. Surg. 2008;34:1521–1526.

7. T. Hellstedt, et al. J. Refract. Surg. 2005;21:236–246.

8. A. Ertan, et al. J. Cataract Refract. Surg. 2007;33:648–653.

9. K.G. Carrasquillo, et al. Cornea 2007;26(8):956–962.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.